glaxo aim high profit fall glaxosmithkline saw profit fall last year 2bn 11 5bn europe's biggest drugmaker say recovery 2005 way cheap copy drug particularly anti depressant paxil wellbutrin weak dollar hit profit global sale 2004 firm confident new drug pipeline deliver profit despite failure obesity drug chief executive jean pierre garnier said difficult year early afternoon trade london company share price 1218 penny mr garnier said company absorbed 5bn lost sale generic still managing grow business continuing success key product mean look forward good performance 2005 said 2005 also important year term research development pipeline progress however firm discontinued development experimental treatment obesity known '771 disappointing clinical trial result glaxo relying new treatment condition cancer diabetes depression hiv aid allergy lift pace sale growth several disappointing year